




RealRate

PHARMACEUTICAL 2020

Kiniksa Pharmaceuticals Ltd.
Rank 246 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

Kiniksa Pharmaceuticals Ltd. Rank 246 of 362

The relative strengths and weaknesses of Kiniksa Pharmaceuticals Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kiniksa Pharmaceuticals Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 243% points. The greatest weakness of Kiniksa Pharmaceuticals Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 214% points.

The company's Economic Capital Ratio, given in the ranking table, is -288%, being 14% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	241,627
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	27,830
Liabilities, Non-Current	1,281
Other Assets	6,509
Other Compr. Net Income	37
Other Expenses	-2,047
Other Liabilities	0
Other Net Income	6,049
Property and Equipment	6,398
Research and Development	135,001
Revenues	0
Selling, General and Administrative Expense	34,962

Output Variable	Value in 1000 USD
Assets	254,534
Liabilities	29,111
Expenses	167,916
Stockholders Equity	225,423
Net Income	-161,867
Comprehensive Net Income	-161,848
Economic Capital Ratio	-288%

